Medicaldevicehub

NCT ID:	NCT00002324
NLM Download Date Description:	N/A
Study First Submitted Date:	1999-11-02
Last Update Submitted Date:	2005-06-23
Last Update Submitted Date:	2005-06-23
Result First Submitted Date:	N/A
Disposition First Submitted Date:	N/A
Start Month Year:	N/A
Start Date:	N/A
Start Date Type:	N/A
Verification Month Year:	August 2002
Verification Date:	2002-08-31
Completion Month Year:	N/A
Completion Date:	N/A
Completion Date Type:	N/A
Primary Completion Month Year:	N/A
Primary Completion Date:	N/A
Primary Completion Date Type:	N/A
Study first Submitted QC Date:	2001-08-30
Study first posted Date:	2001-08-31
Result first Submitted QC Date:	N/A
Result First Posted Date:	N/A
Disposition First Submitted QC Date:	N/A
Disposition First Posted Date:	N/A
Last Updated Submitted QC Date:	2005-06-23
Last Updated Posted Date:	2005-06-24
Target Duration:	N/A
Study Type:	Interventional
Acronym:	N/A
Baseline Population:	N/A
Brief Title:	The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
Official Title:	A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Activity, Safety, and Tolerance of 1) 400 Mg Nevirapine in Combination With 500-600 Mg Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 3-24 Months of Prior Zidovudine Therapy and 200-500 CD4 Cells/mm3 and 2) 400 Mg Nevirapine Versus Nevirapine Placebo in Asymptomatic HIV-1 Nucleoside Naive Patients With 200-500 CD4 Cells/mm3
Overall Status:	Completed
Last Known Status:	N/A
Phase:	Phase 2
Enrollment:	250
Enrollment Type:	N/A
Source:	NIH AIDS Clinical Trials Information Service
Limitation and Caveats:	N/A
Number of Arms:	N/A
Number of Groups:	N/A
Why Stopped:	N/A
Has Expanded Access:	N/A
Expanded Access Type Individual:	N/A
Expanded Access Type Intermediate:	N/A
Expanded Access Type Treatment:	N/A
Has DMC:	N/A
Is it FDA Regulated Drug:	N/A
Is it FDA Regulated Device:	N/A
Is it Unapproved Device:	N/A
Is PPSD:	N/A
Is US Export:	N/A
Is Biospec Retention:	N/A
Biospec Description:	N/A
Plan to Share IPD:	N/A
Plan to Share IPD Description:	N/A
IPD Time Frame:	N/A
IPD Access Criteria:	N/A
IPD URL:	N/A

NCT ID:

NCT00002324

NLM Download Date Description:

N/A

Study First Submitted Date:

1999-11-02

Last Update Submitted Date:

2005-06-23

Last Update Submitted Date:

2005-06-23

Result First Submitted Date:

N/A

Disposition First Submitted Date:

N/A

Start Month Year:

N/A

Start Date:

N/A

Start Date Type:

N/A

Verification Month Year:

August 2002

Verification Date:

2002-08-31

Completion Month Year:

N/A

Completion Date:

N/A

Completion Date Type:

N/A

Primary Completion Month Year:

N/A

Primary Completion Date:

N/A

Primary Completion Date Type:

N/A

Study first Submitted QC Date:

2001-08-30

Study first posted Date:

2001-08-31

Result first Submitted QC Date:

N/A

Result First Posted Date:

N/A

Disposition First Submitted QC Date:

N/A

Disposition First Posted Date:

N/A

Last Updated Submitted QC Date:

2005-06-23

Last Updated Posted Date:

2005-06-24

Target Duration:

N/A

Study Type:

Interventional

Acronym:

N/A

Baseline Population:

N/A

Brief Title:

The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease

Official Title:

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Activity, Safety, and Tolerance of 1) 400 Mg Nevirapine in Combination With 500-600 Mg Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 3-24 Months of Prior Zidovudine Therapy and 200-500 CD4 Cells/mm3 and 2) 400 Mg Nevirapine Versus Nevirapine Placebo in Asymptomatic HIV-1 Nucleoside Naive Patients With 200-500 CD4 Cells/mm3

Overall Status:

Completed

Last Known Status:

N/A

Phase:

Phase 2

Enrollment:

250

Enrollment Type:

N/A

Source:

NIH AIDS Clinical Trials Information Service

Limitation and Caveats:

N/A

Number of Arms:

N/A

Number of Groups:

N/A

Why Stopped:

N/A

Has Expanded Access:

N/A

Expanded Access Type Individual:

N/A

Expanded Access Type Intermediate:

N/A

Expanded Access Type Treatment:

N/A

Has DMC:

N/A

Is it FDA Regulated Drug:

N/A

Is it FDA Regulated Device:

N/A

Is it Unapproved Device:

N/A

Is PPSD:

N/A

Is US Export:

N/A

Is Biospec Retention:

N/A

Biospec Description:

N/A

Plan to Share IPD:

N/A

Plan to Share IPD Description:

N/A

IPD Time Frame:

N/A

IPD Access Criteria:

N/A

IPD URL:

N/A

Detailed Result for NCT00002324